Peripheral arterial disease in older adults: Management of cardiovascular disease risk factors

Journal of Cardiovascular Nursing

Volumn 21, Issue 5 SUPPL. 1, 2006, Pages

  Oka, Roberta K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Exercise; Older adults; PAD; Risk factors

Indexed keywords

AGED; CARDIOVASCULAR DISEASE; DIET THERAPY; EVIDENCE BASED MEDICINE; GERIATRICS; HUMAN; INTERMITTENT CLAUDICATION; KINESIOTHERAPY; METHODOLOGY; MIDDLE AGED; PERIPHERAL VASCULAR DISEASE; REVIEW; RISK ASSESSMENT; RISK FACTOR;

AGED; CARDIOVASCULAR DISEASES; DIET THERAPY; EVIDENCE-BASED MEDICINE; EXERCISE THERAPY; GERIATRICS; HUMANS; INTERMITTENT CLAUDICATION; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; RISK ASSESSMENT; RISK FACTORS;

EID: 33748696815     PISSN: 08894655     EISSN: 15505049     Source Type: Journal    
DOI: 10.1097/00005082-200609001-00005     Document Type: Article

References (65)

1. Hankey GJ, Norman PE, Eikelboom JW. Medical treatment of peripheral arterial disease. JAMA. 2006;295(5):547-553.
2. McDermott M, Greenland P, Liu K, et al. Leg symptoms in peripheral arterial disease. JAMA. 2001;286:1599-1606.
3. Regensteiner J, Hiatt W. Current medical therapies for patients with peripheral arterial disease: a critical review. Am J Med. 2002;112:49-57.
4. McDermott MM, Mehta S, Greenland P. Exertional leg symptoms other than intermittent claudication are common in peripheral arterial disease. Arch Intern Med. 1999;159(4):387-392.
5. Stewart KJ, Hiatt WR, Regensteiner JG, Hirsch AT. Exercise training for claudication. N Engl J Med. 2002;347(24):1941-1951.
6. McDermott MM, Greenland P, Ferrucci L, et al. Lower extremity performance is associated with daily life physical activity in individuals with and without peripheral arterial disease. J Am Geriatr Soc. 2002;50(2):247-255.
7. Oka RK, Szuba A, Giacomini JC, Cooke JP. Gender differences in perception of PAD: a pilot study. Vasc Med. 2003;8(2):89-94.
8. McDermott MM, Greenland P, Liu K, et al. Sex differences in peripheral arterial disease: leg symptoms and physical functioning. J Am Geriatr Soc. 2003;51(2):222-228.
9. Hirsch A, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286:1317-1324.
10. Comerota AJ. The case for early detection and integrated intervention in patients with peripheral arterial disease and intermittent claudication. J Endovasc Ther. 2003;10(3):601-613.
11. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation. 2004;110(6):738-743.
12. Grundy SM. Clinical prevention of coronary heart disease through cholesterol-lowering therapy. Curr Ther Endocrinol Metab. 1997;6:520-526.
13. Criqui M, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326:381-386.
14. Ness J, Aronow WS. Prevalence of coexistence of coronary artery disease, ischemic stroke, and peripheral arterial disease in older persons, mean age 80 years, in an academic hospital-based geriatrics practice. J Am Geriatr Soc. 1999;47(10):1255-1256.
15. Fowkes FG. Epidemiology of peripheral vascular disease. Atherosclerosis. 1997;131(suppl):S29-S31.
16. Hirsch A, Treat-Jacobson D, Lando HA, Hatsukami DK. The role of tobacco cessation, antiplatelet and lipid-lowering therapies in the treatment of peripheral arterial disease. Vasc Med. 1997;2:243-251.
17. Ness J, Aronow WS, Newkirk E, McDanel D. Prevalence of symptomatic peripheral arterial disease, modifiable risk factors, and appropriate use of drugs in the treatment of peripheral arterial disease in older persons seen in a university general medicine clinic. J Gerontol A Biol Sci Med Sci. 2005;60(2):255-257.
18. Planas A, Clara A, Pou JM, et al. Relationship of obesity distribution and peripheral arterial occlusive disease in elderly men. Int J Obes Relat Metab Disord. 2001;25(7):1068-1070.
19. Tornwall ME, Virtamo J, Haukka JK, Aro A, Albanes D, Huttunen JK. Prospective study of diet, lifestyle, and intermittent claudication in male smokers. Am J Epidemiol. 2000;151(9):892-901.
20. Caro J, Migliaccio-Walle K, Ishak K, Proskorovsky I. The morbidity and mortality following a diagnosis of peripheral arterial disease: long-term follow-up of a large database. BMC Cardiovasc Disord. 2005;5(1):14.
21. Gorter PM, Olijhoek JK, van der Graaf Y, et al. Prevalence of the metabolic syndrome in patients with coronary heart disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. Atherosclerosis. 2004;173(2):361.
22. Murabito J, Evans JC, Nieto K, Larson MG, Levy D, Wilson PW. Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. Am Heart J. 2002;143:961-965.
23. Hirsch AT, Hiatt WR. PAD awareness, risk, and treatment: new resources for survival - the USA PARTNERS program. Vasc Med. 2001;6(3):9-12.
24. McDermott MM, Kerwin DR, Liu K, et al. Prevalence and significance of unrecognized lower extremity peripheral arterial disease in general medicine practice.* J Gen Intern Med. 2001;16(6):384-390.
25. McDermott MM, Mandapat AL, Moates A, et al. Knowledge and attitudes regarding cardiovascular disease risk and prevention in patients with coronary or peripheral arterial disease. Arch Intern Med. 2003;163(18):2157-2162.
26. Sukhija R, Yalamanchili K, Aronow WS, Kakar P, Babu S. Clinical characteristics, risk factors, and medical treatment of 561 patients with peripheral arterial disease followed in an academic vascular surgery clinic. Cardiol Rev. 2005;13(2):108-110.
27. Oka RK, Szuba A, Giacomini JC, Cooke JP. A pilot study of I-arginine supplementation on functional capacity in peripheral arterial disease. Vasc Med. In press.
28. McDermott MM, Mehta S, Ahn H, Greenland P. Atherosclerotic risk factor reduction in peripheral arterial disease. J Gen Intern Med. 2002;17(12):895-904.
29. Brown LC, Johnson JA, Majumdar SR, Tsuyuki RT, McAlister FA. Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis. CMAJ. 2004;171(10):1189-1192.
30. Fiegelson H, Criqui M, Fronek A. Diagnosing peripheral arterial disease: the sensitivity, specificity and predictive value of non-invasive tests in a defined population. Am J Epidemiol. 1994;140:518-525.
31. Baumgartner I, Schainfeld R, Graziani L. Management of peripheral vascular disease. Annu Rev Med. 2005;56(1):249-272.
32. Baumgartner I, Schainfeld R, Graziani L. Management of peripheral vascular disease. Annu Rev Med. 2005;56:249-272.
33. Hirsch AT, Haskai ZJ, Hertzer NR, et al. ACC/AHA 2005 Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease). J Am Coll Cardiol. 2006;47(6):e1-e192.
34. Hiatt WR, Hirsch AT, Regensteiner JG, Brass EP. Vascular Clinical Trialists for claudication: assessment of exercise performance, functional status, and clinical end points. Circulation. 1995;92:614-621.
35. Duffield RG, Lewis B, Miller NE, Jamieson CW, Brunt JN, Colchester AC. Treatment of hyperlipidaemia retards progression of symptomatic femoral atherosclerosis. A randomised controlled trial. Lancet. 1983;2(8351):639-642.
36. Blankenhorn DH, Azen SP, Crawford DW, et al. Effects of colestipol-niacin therapy on human femoral atherosclerosis. Circulation. 1991;83(2):438-447.
37. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):145-153.
38. The Diabetes Control and Complication Trial Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol. 1995;75:894-903.
39. Gardner AW. The effect of cigarette smoking on exercise capacity in patients with intermittent claudication. Vasc Med. 1996;1(3):181-186.
40. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ. 1994;308:81-106.
41. Mohler ER 3rd, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation. 2003;108(12):1481-1486.
42. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
43. CAPRIE. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet. 1996;348(9038):1329-1339.
44. Hashiguchi M, Ohno K, Saito R. Studies on the effectiveness and safety of cilostazol, beraprost sodium, prostaglandin E1 for the treatment of intermittent claudication. Yakugaku Zasshi. 2004;124(6):321-332.
45. Girolami B, Bernardi E, Prins M. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med. 1999;159:337-345.
46. Thompson PD, Zimet R, Forbes WP, Zhang P. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol. 2002;90(12):1314-1319.
47. Cooke JP, Oka RK. Atherogenesis and the arginine hypothesis. Curr Atheroscler Rep. 2001;3(3):252-259.
48. Bode-Boger SM, Boger RH, Kienke S, et al. Chronic dietary supplementation with I-arginine inhibits platelet aggregation and thromboxane A2 synthesis in hypercholesterolaemic rabbits in vivo. Cardiovasc Res. 1998;37(3):756-764.
49. Bulling B. The treatment of peripheral arterial occlusive disease with walking (blood vessel) training and Ginkgo biloba extract (EGb 761). In: Clostre F DF, ed. Advances in Ginkgo biloba Extract Research. Paris: Elsevier;143-150.
50. Bauer U. Ginkgo biloba extact, EGb 761, and its effects on the arteries of the leg. In: Clostre F DF ed. Advances in Ginkgo biloba Extract Research. Paris: Elsevier; 121-133.
51. De Feudis F. Ginkgo biloba extract (EGb 761): Pharmacological Activities and Clinical Applications. Paris: Elsevier; 1991.
52. Haramaki N, Nguyen L, Aziz T, Packer L. Ginkgo biloba extract (EGb 761) protects against myocardial ischemiareperfusion injury by acting as an antioxidant. In: Clostre F DF, ed. Advances in Ginkgo biloba Extract Research. Paris: Elsevier.
53. Gardner A, Poehlman E. Exercise rehabilitation programs for the treatment of claudicatoin pain. A meta-analysis. JAMA. 1995;274:975-980.
54. Leng G, Fowler B, Ernst E. Exercise for intermittent claudication. The Cochrane Database of Systematic Reviews, 2000. Art. No: CD000990. DOI: 10.002/14651858.CD000990(2).
55. McDermott MM, Tiukinhoy S, Greenland P, et al. A pilot exercise intervention to improve lower extremity func tioning in peripheral arterial disease unaccompanied by intermittent claudication. J Cardiopulm Rehabil. 2004;24(3):187-196.
56. Gardner AW, Katzel LI, Sorkin JD, Goldberg AP. Effects of long-term exercise rehabilitation on claudication distances in patients with peripheral arterial disease: a randomized controlled trial. J Cardiopulm Rehabil. 2002;22(3):192-198.
57. Cheetham DR, Burgess L, Ellis M, Williams A, Greenhalgh RM, Davies AH. Does supervised exercise offer adjuvant benefit over exercise advice alone for the treatment of intermittent claudication? A randomised trial. Eur J Vasc Endovasc Surg. 2004;27(1):17-23.
58. Gardner AW, Katzel LI, Sorkin JD, et al. Exercise rehabilitation improves functional outcomes and peripheral circulation in patients with intermittent claudication: a randomized controlled trial. J Am Geriatric Soc. 2001;49:755-762.
59. Collins EG, Langbein WE, Orebaugh C, et al. Cardiovascular training effect associated with polestriding exercise in patients with peripheral arterial disease. J Cardiovasc Nurs. 2005;20(3):177-185.
60. NCEP. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
61. Lopes HF, Martin KL, Nashar K, Morrow JD, Goodfriend TL, Egan BM. DASH diet lowers blood pressure and lipid-induced oxidative stress in obesity. Hypertension. 2003;41(3):422-430.
62. Miller ER 3rd, Erlinger TP, Young DR, et al. Results of the Diet, Exercise, and Weight Loss Intervention Trial (DEW-IT). Hypertension. 2002;40(5):612-618.
63. Knoops KT, de Groot LC, Kromhout D, et al. Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE project. JAMA. 2004;292(12):1433-1439.
64. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001;344(1):3-10.
65. de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation. 1999;99(6):779-785.